Mycronic AB (publ) Beat Revenue Forecasts By 15%: Here's What Analysts Are Forecasting Next

Shareholders of Mycronic AB (publ) (STO:MYCR) will be pleased this week, given that the stock price is up 12% to kr427 following its latest third-quarter results. It was a mildly positive result, with revenues exceeding expectations at kr1.8b, while statutory earnings per share (EPS) of kr10.22 were in line with analyst forecasts. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

View our latest analysis for Mycronic

Taking into account the latest results, the most recent consensus for Mycronic from two analysts is for revenues of kr7.28b in 2025. If met, it would imply a modest 4.5% increase on its revenue over the past 12 months. Statutory per-share earnings are expected to be kr17.73, roughly flat on the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr7.17b and earnings per share (EPS) of kr17.54 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at kr477.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Mycronic's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Mycronic's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 3.6% growth on an annualised basis. This is compared to a historical growth rate of 10% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 7.6% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Mycronic.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Mycronic's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for Mycronic going out as far as 2026, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.